Please assess the completion status of the following clinical trial:

Trial Title: Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient receives lorlatinib through Pfizer's expanded access program for treatment of ALK+ neuroblastoma.~* HCP documentation of at least one tumor assessment of response after patient has had at least one dose of lorlatinib~* Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.~Exclusion Criteria:~* Any patient who does not meet any of the inclusion criteria defined in the previous section.

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pediatric Neuroblastoma Patients Treated with Lorlatinib (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).